Skip to main content Skip to footer

Innovative Clinical Trials Center

The forefront of new cancer therapy research
 
 

Some of the most advanced Phase I clinical trials being conducted are offered through the Swim Across America Innovative Clinical Trials Center (ICTC) at Baylor Charles A. Sammons Cancer Center, located on the campus of Baylor University Medical Center, part of Baylor Scott & White Health.

An expansion of the cancer clinical trials offered at Baylor Sammons Cancer Center, our goal for the ICTC is to drive advancements in early cancer detection and new cancer therapy agents through the completion of innovative clinical trials.

What we do

The ICTC consolidates all Phase I trials, offering participating patients one location for clinical examinations, infusions, imaging studies, sample collections for lab work and follow-up.

  • Phase I Clinical Trials Underway
  • Swim Across America
  • ICTC Study Example
  • Contact Us

Phase I Clinical Trials Underway

Representing possible future treatments for:

  • Pancreatic cancer
  • Breast cancer
  • Blood cancers
  • ​Brain tumors
  • Prostate cancer

Swim Across America

The Innovative Clinical Trials Center at Baylor Charles A. Sammons Cancer Center benefits greatly from the support of Swim Across America (SAA), which has a goal to raise more than $1 million over a four-year period for ICTC research. SAA hosts open-water swim events where swimmers chose to swim a half-mile, mile or two-mile course. The participants raise money, competing as a team or individually.

ICTC Study Example

One of our most promising studies funded by SAA has produced some unique developments.

  • A sample collection trial has led to a consistent and uniform group of patient blood samples on which to perform testing—a unique feature in medical research.
  • This sample suppository has opened the door to a new collaboration with the SALK Institute for Biological Studies in California around biomarker identification to potentially measure a patient’s response to his or her treatments.
  • The hope is that there will be a correlation between levels of this biomarker and disease status, thus enabling us to introduce a more accurate form of patient monitoring during the treatment phase.

Contact Us

For more information about the SAA ICTC or clinical trials offered at Baylor Charles A. Sammons Cancer Center at Dallas, please call 214.820.3535.

Scroll To Top